CCL2

CCL2 Full Name

chemokine (C-C motif) ligand 2

CCL2 Introduction

CCL2 (chemokine (C-C motif) ligand 2), also widely known as monocyte chemoattractant protein-1 (MCP-1), has emerged as a critical inflammatory mediator linking immune activation with chronic disease progression. Researchers and drug developers are increasingly focused on CCL2 because persistent inflammation remains a major challenge in oncology, cardiovascular disease, neurodegeneration, and tissue injury repair. As a member of the CC chemokine family, CCL2 primarily recruits monocytes, macrophages, and other immune cells to sites of tissue stress or damage through interactions with receptors such as CCR2, while also showing affinity for CCR1 and CCR4 under certain biological contexts. Recent studies demonstrate that CCL2 expression is tightly regulated by inflammatory cytokines including TNF-α, IL-1β, and IL-6, as well as hypoxia-associated signaling pathways that activate transcription factors such as NF-κB. In cancer biology, constitutive secretion of CCL2 can be further amplified through tumor–stromal interactions, epigenetic regulation, single nucleotide polymorphisms (SNPs), and non-coding RNA networks, making the CCL2 axis an important biomarker and therapeutic target in precision medicine research.

The biological functions of CCL2 extend far beyond simple chemotaxis. In the tumor microenvironment, CCL2 plays a multifaceted role in promoting immune cell infiltration, metabolic remodeling, angiogenesis, and metastatic dissemination. Elevated CCL2 signaling has been associated with breast cancer progression, particularly through synergistic interactions with the HGF/MET pathway that enhance tumor invasiveness and adaptive metabolism. One of the most clinically important findings from recent oncology research is the involvement of CCL2 in resistance to immune checkpoint blockade therapies. Simultaneous activation of the PI3K/AKT and NF-κB pathways can sustain both CCL2 and PD-L1 expression, allowing tumors to maintain immunosuppressive signaling even after PD-1/PD-L1 inhibition. This helps explain why some patients experience poor responses or relapse following immunotherapy. As a result, combined therapeutic strategies targeting both CCL2-mediated inflammation and immune checkpoint pathways are receiving growing attention in translational oncology. Beyond cancer, CCL2 also contributes to wound healing, cardiac remodeling, and tissue regeneration. Experimental myocardial infarction models have shown that cardiac overexpression of CCL2 can activate the JNK/STAT3 signaling axis, stimulate cardiomyocyte proliferation, improve cardiac repair, and reduce ventricular remodeling, highlighting the dual role of CCL2 as both a pathogenic inflammatory driver and a context-dependent regenerative mediator.

The disease relevance of CCL2 is exceptionally broad, which is why it continues to attract interest across multiple biomedical disciplines. In cardiovascular disease, the CCL2/CCR2 axis is considered a major contributor to atherosclerosis because it promotes monocyte recruitment into vascular walls, accelerating plaque formation and chronic vascular inflammation. In neurological disorders, elevated CCL2 expression has been observed in traumatic brain injury, ischemic stroke, spinal cord injury, Alzheimer's disease, and multiple sclerosis. Neurons, astrocytes, microglia, macrophages, and neutrophils can all release CCL2 during central nervous system injury, amplifying neuroinflammatory cascades that contribute to neuronal dysfunction and degeneration. Abnormal microglial activation accompanied by excessive chemokine and reactive oxygen species release is now recognized as a central mechanism underlying many neurodegenerative diseases. Because chronic inflammation is increasingly viewed as a shared biological foundation across aging-related disorders, CCL2 is being investigated not only as a disease biomarker but also as a promising therapeutic intervention point for immunomodulation, anti-inflammatory therapy, regenerative medicine, and next-generation combination treatments.

Alternate Names for CCL2

CCL2; chemokine (C-C motif) ligand 2; HC11; MCAF; MCP1; MCP-1; SCYA2; GDCF-2; SMC-CF; HSMCR30; C-C motif chemokine 2; small-inducible cytokine A2; monocyte secretory protein JE; monocyte chemotactic protein 1; monocyte chemoattractant protein 1; monocyte chemoattractant protein-1; monocyte chemotactic and activating factor; small inducible cytokine subfamily A (Cys-Cys); member 2; small inducible cytokine A2 (monocyte chemotactic protein 1; homologous to mouse Sig-je); anti-MCP-1

• 1.Jin Y, et al.; Chemokine ligand 2: beyond chemotaxis-a multifaceted role in tumor progression. Front Immunol. 2025, 16:1685474.
  2.Guo D, et al.; C-C Motif Chemokine Ligand 2 and Chemokine Receptor 2 in Cardiovascular and Neural Aging and Aging-Related Diseases. Int J Mol Sci. 2024, 25(16):8794.